Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background.
Background. Neurohormonal systems play an important role in chronic heart failure (CHF). Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. We aimed to assess whether genetic background of maximally treated CHF patients predicts variations in LV systolic function and volumes. Methods and Results. We prospectively studied 131 CHF outpatients on optimal treatment for at least six months. Echocardiographic evaluations were performed at baseline and after 12 months. Genotype analysis for ACE I/D, β1adrenergic receptor (AR) Arg389Gly, β2AR Arg16Gly, and β2AR Gln27Glu polymorphisms was performed. No differences in baseline characteristics were detected among subgroups. ACE II was a significant predictor of improvement of LV end-diastolic and end-systolic volume (P = .003 and P = .002, respectively) but not of LV ejection fraction (LVEF); β1AR389 GlyGly was related to improvement of LVEF (P = .02) and LV end-systolic volume (P = .01). The predictive value of polymorphisms remained after adjustment for other clinically significant predictors (P < .05 for all). Conclusions. ACE I/D and β1AR Arg389Gly polymorphisms are independent predictors of reverse remodeling and systolic function recovery in CHF patients under optimal treatment.
Division of Cardiology, Department of Biomedical and Surgical Sciences, University of Verona, 37129 Verona, Italy.
Marzia
M
Rigolli
Mariantonietta
M
Cicoira
Corinna
C
Bergamini
Andrea
A
Chiampan
Andrea
A
Rossi
Corrado
C
Vassanelli
N Engl J Med. 2002 Oct 10;347(15):1135-42
12374873
N Engl J Med. 1992 Sep 3;327(10):669-77
1386652
J Am Coll Cardiol. 1995 Apr;25(5):1154-61
7897129
Circulation. 1995 May 15;91(10):2504-7
7743609
Circulation. 2010 Feb 23;121(7):e46-e215
20019324
J Am Coll Cardiol. 2002 Jul 17;40(2):304-10
12106936
Am J Hum Genet. 1992 Jul;51(1):197-205
1319114
Circulation. 2000 May 2;101(17):2060-5
10790347
Lancet. 1993 Oct 30;342(8879):1073-5
8105309
J Am Coll Cardiol. 2000 Mar 1;35(3):569-82
10716457
Heart. 2000 Sep;84 Suppl 1:i15-7:discussion i50
10956313
J Am Coll Cardiol. 2004 Nov 16;44(10):2019-26
15542286
Circulation. 2009 Apr 14;119(14):e391-479
19324966
Lancet. 1998 Aug;352 Suppl 1:SI8-14
9736474
Am J Med. 2004 May 15;116(10):657-61
15121491
J Card Fail. 2002 Dec;8(6 Suppl):S486-90
12555162
Biotechniques. 1991 Apr;10(4):506-13
1867860
J Am Coll Cardiol. 2001 Jun 1;37(7):1808-12
11401115
J Hypertens. 1998 Dec;16(12 Pt 2):1879-83
9886872
Pharmacogenet Genomics. 2007 Nov;17(11):941-9
18075464
Am Heart J. 2001 Oct;142(4):704-13
11579363
J Am Coll Cardiol. 2008 Aug 19;52(8):644-51
18702968
J Am Coll Cardiol. 1996 Jul;28(1):162-7
8752809
N Engl J Med. 2000 Apr 13;342(15):1120-2
10760314
Ann Intern Med. 1996 Jul 1;125(1):19-25
8644984
Eur J Heart Fail. 2003 Aug;5(4):463-8
12921807
J Biol Chem. 1999 Apr 30;274(18):12670-4
10212248
Cardiovasc Drugs Ther. 2004 Jan;18(1):57-66
15115904
Am J Cardiol. 1996 Aug 1;78(3):362-4
8759823